405 filings
Page 14 of 21
6-K
jse2xi11 4tghp
23 Feb 15
Current report (foreign)
12:00am
SC 13G/A
bah3 jzk7l
13 Feb 15
Intellipharmaceutics International Inc.
12:00am
6-K
pn7q4iwes4 vkhwo
2 Feb 15
Current report (foreign)
12:00am
424B5
be1ab6j2
22 Dec 14
Prospectus supplement for primary offering
12:00am
424B5
li9tk
22 Dec 14
Prospectus supplement for primary offering
12:00am
6-K
l1byrdd 2ea
20 Nov 14
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR® generic by Teva
12:00am
6-K
fx5i 6vy53
18 Nov 14
Intellipharmaceutics Announces Appointment of New Chief Financial Officer
12:00am
6-K
iekwxty0lz8k
27 Oct 14
Intellipharmaceutics Reports that the FDA has Given Its Toronto Manufacturing Facility an “Acceptable” Classification
12:00am
6-K
fiarcr9erf95eapl82
22 Oct 14
Current report (foreign)
12:00am
6-K
lq6v 40v6jmwo
15 Oct 14
Current report (foreign)
12:00am
6-K
igmaz5nx
30 Sep 14
Intellipharmaceutics Announces Resignation of Chief Financial Officer
12:00am
6-K
wn2mzcs9tpd cndbq
28 Aug 14
Intellipharmaceutics Augments its Rexista™ Oxycodone Development Program with Novel Overdose Deterrence Technology
12:00am
6-K
sxs l5pgs
8 Jul 14
Current report (foreign)
12:00am
424B3
upizppve
4 Jun 14
Prospectus supplement
12:00am
EFFECT
2yiwi0hvjkp
4 Jun 14
Notice of effectiveness
12:00am
6-K
33m913wqnwmu
21 May 14
Current report (foreign)
12:00am
F-3
37i 4rrb9wtyj
20 May 14
Shelf registration (foreign)
12:00am
CT ORDER
e5vx7ojj
28 Apr 14
Confidential treatment order
12:00am
6-K
lde bslu648hel6lyy2c
14 Apr 14
Current report (foreign)
12:00am
20-F/A
qwcopa5wmu92s7o70
14 Apr 14
Annual report (foreign) (amended)
12:00am